Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, describes results from a phase II study that examined PD 0332991, an oral selective inhibitor of cyclin-dependent kinase 4/6, in combination with letrozole as a first-line treatment for postmenopausal women with metastatic ER-positive breast cancer.
To view more coverage from SABCS, visit [ Ссылка ]
